Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Q2 2025 Earnings Presentation
14 slides from Day One Biopharmaceuticals's earnings presentation, Aug 5, 2025
Slide 1: Second Quarter 2025 Financial Results & Corporate Progress
AUGUST 2025 Second Quarter 2025 Financial Results & Corporate Progress
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc
Slide 3: Agenda & Day One Participants
Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM Launch Performance Lauren Merendino (Chief Commercial Officer) Financial Performance Charles York (Chief Operating & Chief Financial Officer) Q&A Session All, joined by: Mike Vasconcelles (Head of R&D)
Slide 4: Opening Remarks
Opening Remarks Jeremy Bender Chief Executive Officer
Slide 5: Second Quarter 2025 Highlights
EMA: European Medicines Agency 1 Regulatory submission process executed by Ipsen 2 Represents cash, cash equivalents and short-term investments as of June 30, 2025. Net revenue for the most recent 12 months represents results for the 12-month period ended June 30, 2025. Second Quarter 2025 Highlight
Slide 6: OJEMDA Launch Performance
OJEMDA Launch Performance Lauren Merendino Chief Commercial Officer
Slide 7: Commercial Performance by the Numbers
Commercial Performance by the Numbers $33.6M Q2 2025 OJEMDA Net Product Revenue 1,062 1 Prescriptions are approximations based on data available as of June 30, 2025. 2 Second quarter 2024 reflects a partial quarter following OJEMDA receiving U.S. FDA accelerated approval for relapsed or refractory B
Slide 8: One Year In: OJEMDA Delivering Steady Revenue Growth
1 Q3 2024 and Q4 2024 revenue included approximately $1.6M and $1.4M, respectively of revenue associated with Ex-US sales which has been removed for the purposes of calculating compounded quarterly revenue growth rate. 2 Compounded quarterly growth represents the comparison of Q3 2024 to Q2 2025. Ne
Slide 9: One Year In: Consistent Uptake Driving Quarterly OJEMDA Growth
Prescriptions For The Most Recent 12 Months OJEMDA Prescriptions (TRx)1 +15% One Year In: Consistent Uptake Driving Quarterly OJEMDA Growth Achieved greater than 1,000 scripts in Q2 2025 Prescription Highlights Strong and consistent patient demand, driven by new patient starts and high percentage of
Slide 10: Expanding Prescriber Adoption with Meaningful Growth Opportunity Remaining
Expanding Prescriber Adoption with Meaningful Growth Opportunity Remaining Launch Dec 2024 Jun 2025 1 Patient 2-3 Patients 4-5 Patients Growing Depth of Prescribing by Account Since Launch 6+ Patients Continued growth in breadth of unique prescribers initiating at least one patient on OJEMDA Growth
Slide 11: OJEMDA Priorities to Drive Revenue Growth in 2025
OJEMDA Priorities to Drive Revenue Growth in 2025 r/r, relapsed or refractory. Drive depth of prescribing with current prescribers Encourage non-user HCPs to try OJEMDA in their next r/r pLGG patient Establish OJEMDA as standard of care in 2nd line r/r BRAF-altered pLGG Support prescribers and patie
Slide 12: Financial Performance
Financial Performance Charles York Chief Operating Officer & Chief Financial Officer
Slide 13: Second Quarter 2025 Financial Results
All financial information as of 6/30/25 is unaudited. 1 Includes stock-based compensation expense of $3.6 million and $7.8 million for the three and six months ended 6/30/25, and $4.7 million and $9.4 million for the three and six months ended 6/30/24. 2 Includes stock-based compensation expense of
Slide 14: Thank You
Thank You
Day One Biopharmaceuticals — Q2 2025 Earnings Presentation on 6ix